TScan reports positive Phase 1 ALLOHA data; plans registrational trial for TSC-101 in H2 2025

TScan Therapeutics, Inc.

Event-free survival strongly favored treatment arm (HR=0.30, p=0.04); relapse probability trended lower (HR=0.28, p=0.14).
2 of 26 (8%) treatment-arm patients relapsed vs 4 of 12 (33%) controls; median time to relapse not evaluable vs 160 days.
No TP53-mutated patients relapsed in treatment arm (0/4 infused), while both control-arm TP53 patients relapsed within 6 months and died.
Registrational trial for TSC-101 planned for H2 2025 with RFS primary endpoint, powered at HR 0.60, 85% power, ~140 treatment subjects.
Solid tumor program: 8 patients infused singleplex; first T-Plex product manufactured; IND for MAGE-A4 TCR submitted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.